Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XENON XE 133 vs LYMPHOSEEK KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xenon Xe 133 is a radioactive gas that emits gamma radiation. It is used as a tracer in pulmonary ventilation studies and regional cerebral blood flow measurements. The mechanism relies on its physical properties as an inert radioactive gas that diffuses across alveolar-capillary membranes and is distributed according to regional ventilation and perfusion.
Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.
Pulmonary ventilation imaging (FDA approved),Regional cerebral blood flow evaluation (FDA approved)
For lymphoscintigraphy to assist in the localization of sentinel lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.
5-10 m Ci (185-370 MBq) inhaled or intravenously as a single dose for pulmonary ventilation/perfusion imaging.
Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.
Terminal elimination half-life: 1.5–2 minutes (fast washout from well-perfused tissues); total-body elimination half-life approximately 5–7 minutes due to slow release from adipose tissue. Clinical context: rapid clearance allows repeated imaging within short intervals.
6 hours (physical half-life of technetium-99m). Effective half-life is approximately 6 hours, allowing imaging up to 24 hours post-injection.
Xenon Xe 133 is inert and not metabolized; it is eliminated unchanged via exhalation.
Technetium Tc-99m tilmanocept is not metabolized; it is cleared from the injection site via the lymphatic system and excreted renally.
Primarily eliminated via exhalation through the lungs (>95% unchanged); minimal renal excretion (<5% as dissolved gas).
Renal: 100% (as technetium-99m pertechnetate). No biliary or fecal elimination.
Negligible (<5%); Xenon is a noble gas and does not bind appreciably to plasma proteins.
Negligible (<5%), primarily to albumin.
Volume of distribution: 13–15 L/kg (large due to high lipid solubility, extensive distribution into fat and other tissues). Clinical meaning: indicates rapid and widespread tissue uptake, with adipose tissue as a slow-release reservoir.
Approximately 0.2 L/kg, indicating distribution within extracellular fluid.
Inhalation: near 100% (gas is fully absorbed from alveoli into the bloodstream; intravenous injection not used clinically).
Not applicable (administered parenterally).
No dose adjustment required; xenon is eliminated via exhalation.
No dose adjustment required based on GFR, but ensure adequate hydration.
No dose adjustment required; xenon elimination is independent of hepatic function.
No specific guidelines available; use with caution in severe hepatic impairment.
0.1-0.3 m Ci/kg (3.7-11.1 MBq/kg) inhaled or intravenous, minimum 2 m Ci (74 MBq), maximum 10 m Ci (370 MBq).
Not established; safety and efficacy in pediatric patients have not been studied.
Use lowest effective dose; consider reduced respiratory function but no specific dose adjustment required.
No specific dosage adjustment; monitor for adverse effects as elderly may have reduced immune response.
None.
This drug does not have a black box warning.
Radiation exposure risk; minimize dose and duration.,Use with caution in patients with impaired pulmonary function.,Pregnancy category C; use only if benefit outweighs risk.,Lactation: discontinue nursing or drug.,Ensure adequate ventilation to prevent accumulation of exhaled gas.
Risk of hypersensitivity reactions including anaphylaxis.,Not for intrathecal administration.,Radiation exposure risk.
None specifically documented; contraindicated in patients with known hypersensitivity to xenon or components.
Known hypersensitivity to tilmanocept or any component of the formulation.
No food or drug interactions; no dietary restrictions required with Xenon Xe 133.
No known food interactions. No dietary restrictions required.
Xenon Xe 133 is a radioactive gas used for diagnostic imaging. Limited data in pregnancy; radiation exposure carries risk of teratogenicity, especially during organogenesis (first trimester). Use only if benefit outweighs risk. Second and third trimester risk is lower but consider fetal radiation exposure.
Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended doses. However, if administered intravenously, radiation exposure to the fetus could occur. No teratogenic effects are expected from the non-radioactive component (tilmanocept). Pregnancy category not assigned by FDA for diagnostic radiopharmaceuticals. Use only if clearly needed.
No data on excretion in breast milk. Discontinue breastfeeding temporarily after administration. Advise pump and discard milk for at least 24 hours post-exposure. M/P ratio unknown.
It is unknown whether tilmanocept is excreted in human milk. Because of the low dose and local administration, systemic exposure is minimal. However, to minimize radiation exposure to the nursing infant, temporary cessation of breastfeeding for 4-6 hours after administration is recommended. M/P ratio not available.
No dose adjustment is recommended based on pharmacokinetic changes; however, consider minimizing fetal radiation exposure by using lowest effective dose and shortest scan time.
No dose adjustment necessary. The administered activity of technetium Tc 99m tilmanocept is typically 18.5-74 MBq (0.5-2.0 m Ci) regardless of pregnancy. Pharmacokinetic changes in pregnancy are not expected to require dose modification due to local subcutaneous administration.
Xenon Xe 133 is a radiopharmaceutical gas used for pulmonary ventilation scintigraphy. Its short half-life (5.24 days) allows for serial studies with minimal radiation exposure. Ensure patient has not recently undergone other nuclear medicine studies to avoid interference. Administer via closed breathing system to prevent environmental contamination. Image acquisition typically during equilibrium and washout phases. Adverse effects are rare but include dizziness, headache, or metallic taste.
Lymphoseek (technetium Tc 99m tilmanocept) is a receptor-targeted radiotracer for sentinel lymph node mapping. Administer intradermally, subcutaneously, or peritumorally. Optimal imaging time: 15-60 min post-injection. Can be used in patients with penicillin allergy as it contains no penicillin. Ensure patient is not pregnant or lactating. May cause injection site reactions.
This is a radioactive gas used to image lung function.,You will inhale the gas through a mouthpiece or mask while lying under a camera.,The amount of radiation is very low and considered safe.,No special precautions are needed after the test; you can resume normal activities.,Drink plenty of fluids after the test unless instructed otherwise.
This is a radioactive dye used to find lymph nodes during surgery.,You will receive a small injection near the tumor site.,The procedure is generally safe, but inform your doctor if you are pregnant or breastfeeding.,You may experience mild pain, redness, or swelling at the injection site.,No special dietary restrictions are needed before the procedure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XENON XE 133 vs LYMPHOSEEK KIT, answered by our medical review team.
XENON XE 133 is a Radiopharmaceutical Diagnostic Agent that works by Xenon Xe 133 is a radioactive gas that emits gamma radiation. It is used as a tracer in pulmonary ventilation studies and regional cerebral blood flow measurements. The mechanism relies on its physical properties as an inert radioactive gas that diffuses across alveolar-capillary membranes and is distributed according to regional ventilation and perfusion.. LYMPHOSEEK KIT is a Radiopharmaceutical Diagnostic Agent that works by Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XENON XE 133 and LYMPHOSEEK KIT depend on the specific clinical indication. These are both Radiopharmaceutical Diagnostic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XENON XE 133 is: 5-10 m Ci (185-370 MBq) inhaled or intravenously as a single dose for pulmonary ventilation/perfusion imaging.. The standard adult dose of LYMPHOSEEK KIT is: Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XENON XE 133 and LYMPHOSEEK KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XENON XE 133 is classified as Category C. Xenon Xe 133 is a radioactive gas used for diagnostic imaging. Limited data in pregnancy; radiation exposure carries risk of teratogenicity, especially during organogenesis (first . LYMPHOSEEK KIT is classified as Category C. Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.